At the time of this post, the COVID-19 pandemic has impacted 188 countries, with 4.5 million confirmed cases worldwide and more than 300,000 deaths. Families are mourning, businesses are filing for bankruptcy, and those who have not yet suffered tangible loss are overwhelmed with fear and unanswered questions.
You’ve been waiting for this moment. After more than 12 years of medical school and training, the operating room is yours for the first time as an attending surgeon. You walk into the OR, expecting the same setup and routine that you used all through fellowship. But wait a second… you see a beanbag and wonder if people even still use those.
Dr. Sara J. Pereira shares her experience in Birmingham, Alabama, describing how the pandemic has created a renewed role for telemedicine and the reality of disease progression in patients whose care has been delayed.
Dr. Vinod H. Thourani describes how the coronavirus pandemic is affecting cardiothoracic surgeons and their patients and how the specialty is uniquely equipped to handle the high-intensity work of actively managing COVID-19 patients.
There comes a time in every leader’s job where a crisis emerges. In the Oxford English dictionary, the word “crisis” is defined as “a time of great danger, difficulty, or confusion when problems must be solved or important decisions must be made.”
The new decade is off to a dramatic start. Across the globe, Australia was devastated by wildfires, and hitting us much closer to home, Nashville was simultaneously struck by four tornadoes, and Utah was shaken by earthquakes.
7 min read
Drs. Erin A. Gillaspie, Gabriel Loor, & Mara B. Antonoff
Dr. T. Sloane Guy describes how the coronavirus pandemic is affecting hospitals and patients in the US and what it means for the cardiothoracic surgery specialty.
Dr. Alan D. L. Sihoe offers an international perspective on COVID-19 and shares his personal experience and thoughts on how the coronavirus pandemic has affected Hong Kong and what it means for the rest of the world.
Dr. Douglas E. Wood describes the findings from the NELSON trial and what they mean for policy and program development for lung cancer early detection through CT screening.
Dr. Thomas E. MacGillivray explains how the ISCHEMIA trial does not negate or even contradict the multiple previous clinical trials demonstrating the superiority of surgical revascularization over medical therapy (or PCI) in patients with specific anatomic patterns of coronary artery disease.
